APLI — Appili Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$1.99m
- CA$14.23m
- CA$0.10m
Brief: Appili Therapeutics Announces Pricing Of Overnight Marketed Equity Offering
Brief: Appili Therapeutics Inc - Will Undertake An Overnight Marketed Public Offering Of Units
Brief: Appili Therapeutics, AiPharma Announce Strategic Alliance And Equity Transaction
Brief: Appili Therapeutics Enrolls Last Patient In Phase 3 Trial Of Oral Avigan/Reeqonus For Treatment Of Mild-To-Moderate COVID-19
Brief: Appili Therapeutics Completes Enrollment For COVID-19 Viral Shedding Sub-Study
Brief: Appili Therapeutics Reports Financial And Operational Results For First Quarter Of Fiscal Year 2022
Brief: Appili Therapeutics Reports Provides Update On Strategy For Fiscal 2022
Brief: Appili Therapeutics Inc. Expands Preseco Clinical Trial Of Avigan®/Reeqonus™ For Mild-To-Moderate Covid-19 Patients Into Mexico And Brazil
Brief: Independent Data Safety Monitoring Board Recommends Appili Complete Phase 3 Avigan/Reeqonus Trial
Brief: Appili Therapeutics Appoints Veteran Healthcare Executive Rochelle Stenzler To Its Board Of Directors
Brief: Appili Therapeutics Provides Enrollment Update For Its Phase 3 PRESECO Trial Evaluating Oral Antiviral Favipiravir As An Early Treatment In Covid-19
India's Dr.Reddy's ends study of COVID-19 drug Avigan in Kuwait (updated)
Brief: Dr. Reddy's Canada Filed Application On Behalf Of Consortium For Reeqonus Tablets For Acute Treatment Of Mild-Moderate Covid-19 Adults
Brief: Appili Therapeutics Inc Expects To Report Early Data From Preseco Study In First Half Of 2021
Brief: Health Canada Clears Appili Therapeutics For New Phase 3 Clinical Trial To Evaluate Avigan Tablets In The Prevention Of Covid-19
Brief: Appili Therapeutics Reports Financial And Operational Results For Second Quarter Of Fiscal Year 2021
Brief: Appili Therapeutics Signed A Collaboration, Development And Supply Agreement With Dr. Reddy's Laboratories And Global Response Aid
Brief: Appili Therapeutics Appoints Drug Development Executive Don Cilla To Chief Development Officer
Brief: Appili Therapeutics Announces Additional Funding For Its ATI-1701 Biodefense Program